CTOs on the Move

Lyra Therapeutics

www.lyratherapeutics.com

 
Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra`s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
John Bishop
Chief Technology Officer Profile

Funding

Lyra Therapeutics raised $30M on 01/29/2020
Lyra Therapeutics raised $100.5M on 04/08/2022

Similar Companies

Qualitest Pharmaceuticals

Qualitest Pharmaceuticals is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biocodex

Biocodex is a San Bruno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BTL Industries

Founded in 1993, BTL has grown to become one of the world’s major manufacturers of medical equipment. BTLs major segments include physical therapy, cardiology and medical aesthetics.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.

Agile Therapeutics

Agile Therapeutics is a forward-thinking women`s healthcare company dedicated to fulfilling the unmet health needs of today`s women. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Twirla® and our pipeline products are based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin.